
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Click here to answer our new AAD 2023 poll.
What are you most looking forward to at AAD 2023?
If you can't attend AAD 2023,






